FindTrial
Sign In

Research on AKK bacteria and butyrate regulation in asthma desensitization therapy

Study on the mechanism of allergen immunotherapy in children with asthma regulated by AKK bacteria and its metabolite butyrate through the AhR-Treg/Th17 signaling axis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118973
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Observation group:None

Sponsors

The Second Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Children aged 5-14 who undergo allergen immunotherapy in our hospital; 2. Children who do not suffer from infectious diseases such as HIV and other sexually transmitted diseases, and have no family history of genetic diseases such as Down's syndrome; 3. Children whose parents both agree to participate and are willing to cooperate in providing information and fecal specimens (by signing an informed consent form).

Exclusion criteria

Exclusion criteria: 1. Individuals with infectious diseases such as HIV and other sexually transmitted diseases, or those with a family history of genetic diseases; 2. Being unable to provide information materials and child fecal specimens on time.

Design outcomes

Primary

MeasureTime frame
Akkermansia muciniphila,butyrate;Total asthma symptom score (TASS) and total drug score (TMS);—

Countries

China

Contacts

Public ContactXiaoxiao Jia

The Second Affiliated Hospital of Wenzhou Medical University

395477104@qq.com+86 577 88002174

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026